Compare FedEx Corporation (FDX) vs Neurocrine Biosciences Inc (NBIX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
FedEx Corporation vs Neurocrine Biosciences Inc — how do they compare? FedEx Corporation trades at $290.91 (market cap $69.04B), while Neurocrine Biosciences Inc trades at $142.16 (market cap $14.36B). The key difference: FedEx Corporation is far larger — about 4.8× Neurocrine Biosciences Inc's market cap, and FedEx Corporation pays a 1.67% dividend while Neurocrine Biosciences Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold FedEx Corporation for 87 Days and Neurocrine Biosciences Inc for 23 Days on average.
| FDX | NBIX | |
|---|---|---|
Market Cap | $69.04B | $14.36B |
Volume | 1,287,367 | 1,237,180 |
Sector | Industrials | Health |
52-Week High | $339.35 | $185.50 |
52-Week Low | $180.87 | $123.10 |
Typical Hold Time | 87 Days | 23 Days |
Enterprise Value | $98.68B | $14.37B |
Dividend Yield | 1.67% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FedEx (FDX) trades at $289.04, showing minimal daily change. The stock exhibits a bearish technical signal with key support at $288 and resistance at $290. Fundamentally, the company maintains stable profitability with a net income margin of 4.68% and a P/E ratio of 15.73, while recent earnings beats in Q4 2025 and Q1 2026 highlight operational strength. Positive developments include a $300 million electric truck order and shareholder approval of executive compensation, though rising fuel prices present a near-term headwind.
The outlook for FDX is cautiously optimistic, supported by analyst consensus favoring a buy rating with a $307.55 price target. Investment appeal lies in its reasonable valuation and dividend yield, but risks include margin pressure from fuel costs, competitive intensity, and macroeconomic sensitivity. The stock's trajectory will likely hinge on execution of cost initiatives and freight demand trends.
Neurocrine Biosciences (NBIX) trades at $141.69, down 1.24% on the day, with a bearish technical signal from moving averages. Fundamentally, the company shows strong profitability with a 20.91% net income margin and consistent earnings beats, including a significant Q2 2026 beat. Recent news highlights pipeline advancements and executive appointments, while analyst sentiment remains overwhelmingly positive.
The outlook for NBIX is supported by robust fundamentals and strong analyst buy ratings, but near-term price action is challenged by technical bearishness. Key opportunities include product diversification and pipeline growth, while risks involve execution of expansion plans and potential pricing pressures on key products like INGREZZA.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About FedEx Corporation
FedEx pioneered overnight delivery in 1973 and remains the world's largest express package provider. In its fiscal 2020 (ended May 2020), FedEx derived 51% of revenue from its express division, 33% from ground, and 10% from freight, its asset-based less-than-truckload shipping segment. The remainder comes from other services, including FedEx Office, which provides document production/shipping, and FedEx Logistics, which provides global forwarding. FedEx acquired Dutch parcel delivery firm TNT Express in 2016. TNT was previously the fourth-largest global parcel delivery provider.
Read more on FDX →About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →
